{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'medication and for at least 2 weeks after the last dose of study medication.', 'The investigator should evaluate the effectiveness of the contraceptive method', 'in relationship to the first dose of study intervention.', 'The investigator is responsible for ensuring that participants understand how to properly', 'use these methods of contraception.', 'All participants in the study should be counselled on safer sexual practices including the', 'use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of', 'HIV transmission to an uninfected partner.', 'The investigator is responsible for review of medical history, menstrual history, and', 'recent sexual activity to decrease the risk for inclusion of a woman with an early', 'undetected pregnancy', 'Informed Consent', '7. Capable of giving signed informed consent as described in Appendix 10 which', 'includes compliance with the requirements and restrictions listed in the informed', 'consent form and in this protocol.', 'Other', '8. Participants enrolled in France must be affiliated to, or a beneficiary of, a social', 'security category.', '5.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', 'Concurrent Conditions/Medica History', '1. Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed', 'during the study', '2. Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3', \"disease [CDC, 2014], EXCEPT cutaneous Kaposi's sarcoma not requiring systemic\", 'therapy. Historical or current CD4 cell counts less than 200 cells/mm\u00b3 are NOT', 'exclusionary.', '3. Participants with severe hepatic impairment (Class C) as determined by Child-Pugh', 'classification (see Section 11.5).', '4. Unstable liver disease (as defined by the presence of ascites, encephalopathy,', 'coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent', \"jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's\", 'syndrome or asymptomatic gallstones).', '5. Evidence of Hepatitis B virus (HBV) infection based on the results of testing at', 'Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-', 'HBc), Hepatitis B surface antigen antibody (anti-HBs) and HBV DNA as follows:', 'Participants positive for HBsAg are excluded.', 'Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg', 'status) and positive for HBV DNA are excluded.', '40']['2017N331008_0', 'CONFIDENTIAL', '208090', 'Note: Participants positive for anti-HBc (negative HBsAg status) and positive for', 'anti-HBs (past and/or current evidence) are immune to HBV and are not excluded.', 'Anti-HBc must be either total anti-HBc or anti-HBc immunoglobulin G (IgG), and', 'NOT anti-HBc IgM. Participants with a documented history of chronic HBV and', 'current undetectable HBV DNA while on a TAF/TDF regimen are excluded.', '6. Anticipated need for any hepatitis C virus (HCV) therapy during the randomized', 'phase of the study, or anticipated need for HCV therapy with a potential for adverse', 'drug-drug interactions with DTG or 3TC.', '7. Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without', 'clear documentation of treatment). Participants who are at least 7 days post', 'completed treatment are eligible.', '8. History or presence of allergy or intolerance to the study interventions or their', 'components or drugs of their class.', \"9. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or\", 'resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile', 'intraepithelial neoplasia.', \"10. Participants who in the investigator's judgment, poses a significant suicidality risk\", '11. Any pre-existing physical or mental condition which, in the opinion of the', \"Investigator, may interfere with the participant's ability to comply with the dosing\", 'schedule and/or protocol evaluations or which may compromise the safety of the', 'participant.', '12. Any condition which, in the opinion of the Investigator, may interfere with the', 'absorption, distribution, metabolism or excretion of the study interventions or render', 'the participant unable to take oral medication.', 'Exclusionary Treatments Prior to Screening or Day 1', '13. Use of any regimen consisting of single or dual ART (peri-partum treatment with', 'single dose nevirapine is allowed).', '14. Current use of stavudine, didanosine, or nelfinavir', '15. Participants receiving any prohibited medication listed in Section 11.6 and who are', 'unwilling or unable to switch to an alternate medication', '16. Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening;', '17. Treatment with any of the following agents within 28 days of Screening', 'radiation therapy', 'cytotoxic chemotherapeutic agents', 'any systemic immune suppressant', '18. Exposure to an experimental drug or experimental vaccine within either 28 days, 5', 'half-lives of the test agent, or twice the duration of the biological effect of the test', 'agent, whichever is longer, prior to the first dose of IP.', '41']\n\n###\n\n", "completion": "END"}